X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (135) 135
female (129) 129
oncology (122) 122
breast neoplasms - drug therapy (83) 83
index medicus (83) 83
middle aged (82) 82
breast cancer (80) 80
breast neoplasms - pathology (72) 72
chemotherapy, adjuvant (61) 61
breast neoplasms - surgery (60) 60
chemotherapy (58) 58
cancer (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
surgery (43) 43
aged (42) 42
adult (40) 40
prognosis (38) 38
disease-free survival (34) 34
treatment outcome (34) 34
tamoxifen (32) 32
breast neoplasms - mortality (30) 30
neoplasm staging (30) 30
surgical adjuvant breast (29) 29
neoadjuvant therapy (28) 28
cyclophosphamide - administration & dosage (27) 27
article (26) 26
doxorubicin - administration & dosage (26) 26
antineoplastic agents, hormonal - therapeutic use (24) 24
breast neoplasms - therapy (24) 24
combined modality therapy (24) 24
mastectomy, segmental (24) 24
medicine & public health (24) 24
survival analysis (24) 24
women (24) 24
adjuvant treatment (23) 23
mastectomy (23) 23
follow-up studies (22) 22
lymphatic metastasis (22) 22
randomized controlled trials as topic (22) 22
tamoxifen - therapeutic use (22) 22
trastuzumab (22) 22
clinical trials (21) 21
preoperative chemotherapy (21) 21
therapy (21) 21
breast neoplasms - radiotherapy (19) 19
radiation-therapy (19) 19
radiotherapy (19) 19
trial (18) 18
care and treatment (17) 17
lumpectomy (17) 17
randomized-trial (17) 17
risk factors (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
biopsy (16) 16
cancer therapies (16) 16
sentinel lymph node biopsy (16) 16
survival rate (16) 16
carcinoma (15) 15
original reports (15) 15
survival (15) 15
taxoids - administration & dosage (15) 15
antineoplastic agents - therapeutic use (14) 14
docetaxel (14) 14
health aspects (14) 14
surgical oncology (14) 14
time factors (14) 14
neoadjuvant chemotherapy (13) 13
paclitaxel - administration & dosage (13) 13
receptors, estrogen - analysis (13) 13
research (13) 13
breast neoplasms - chemistry (12) 12
clinical trials as topic (12) 12
drug therapy (12) 12
hematology, oncology and palliative medicine (12) 12
medicine, general & internal (12) 12
neoplasm recurrence, local - pathology (12) 12
tumors (12) 12
analysis (11) 11
breast neoplasms - genetics (11) 11
cyclophosphamide (11) 11
doxorubicin (11) 11
drug administration schedule (11) 11
patient outcomes (11) 11
postmenopausal women (11) 11
proportional hazards models (11) 11
prospective studies (11) 11
risk (11) 11
20-year follow-up (10) 10
abridged index medicus (10) 10
bc5 (10) 10
local recurrence (10) 10
male (10) 10
mammography (10) 10
medical colleges (10) 10
metastases (10) 10
paclitaxel (10) 10
radiation therapy (10) 10
radiotherapy, adjuvant (10) 10
receptors, estrogen - metabolism (10) 10
risk assessment (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Surgical Oncology, ISSN 1068-9265, 8/2018, Volume 25, Issue 8, pp. 2124 - 2126
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1245/s10434-018-6537-z 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | BREAST-CANCER | TRIAL | SURGERY | NODE BIOPSY | ONCOLOGY | DISSECTION | METASTASES | Breast Neoplasms - surgery | Breast Neoplasms - pathology | Humans | Axilla | Female | Neoadjuvant Therapy | Sentinel Lymph Node Biopsy | Lymph Node Excision - standards | Breast Neoplasms - drug therapy | Adjuvant treatment | Cancer
Journal Article
The Breast Journal, ISSN 1075-122X, 11/2019, Volume 25, Issue 6, pp. 1192 - 1197
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer consisting of various combinations of malignant epithelial and mesenchymal... 
treatment | targeted therapies | systematic review | metaplastic breast carcinoma | Breast cancer | Carcinoma | Health aspects | Cancer | Breast carcinoma | Heterogeneity | Mesenchyme | Physicians | Invasiveness | Growth patterns | Health risks | Breast | Mammary gland
Journal Article
Oncology Times, ISSN 0276-2234, 10/2019, Volume 41, Issue 20, pp. 1 - 6
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 05/2015, Volume 22, Issue 5, pp. 1425 - 1433
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 927 - 933
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 25, pp. 3366 - 3373
Journal Article
npj Breast Cancer, ISSN 2374-4677, 12/2018, Volume 4, Issue 1, pp. 27 - 6
In contemporary management of early-stage breast cancer, clinical decisions regarding adjuvant systemic therapy are increasingly made after considering both... 
Chemotherapy | Breast cancer | Cancer therapies | Medical prognosis
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 10, pp. 1677 - 1683
Purpose The 21-gene OncotypeDX recurrence score (RS) assay quantifies the risk of distant recurrence in tamoxifen-treated patients with node-negative, estrogen... 
MASTECTOMY | BENEFIT | SURGICAL ADJUVANT BREAST | ONCOLOGY | TAMOXIFEN | GENE-EXPRESSION | PATTERNS | RANDOMIZED CLINICAL-TRIALS | <